Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for relapsed myeloma: Triple-Drug cocktail under study

NCT ID NCT02244125

Completed Disease control Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of three drugs—pomalidomide, cyclophosphamide, and dexamethasone—in 100 patients with multiple myeloma that had returned after initial treatment. All patients had previously been part of the IFM/DFCI 2009 trial. The goal was to see how many patients responded after four cycles of treatment. The study is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pomalidomide, cyclophosphamide, and dexamethasone
What this could lead to
If successful, this combination could offer a new treatment option for multiple myeloma patients whose cancer has returned after initial therapy.
What could go wrong
This is a phase 2 trial with only 100 patients, so results may not apply to everyone. Side effects from the drugs can be serious, and the cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FIRST RELAPSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FIRST RELAPSE MULTIPLE MYELOMA

Contacts and locations

Locations

  • CHRU - Hôpital Claude Huriez

    Lille, 59037, France

  • CHRU Dijon

    Dijon, 21000, France

  • CHRU Hopital Bretonneau

    Tours, 37044, France

  • CHRU Hopital Pontchaillou

    Rennes, 35033, France

  • CHRU Hopital Saint Antoine

    Paris, 75012, France

  • CHRU Hopital Sud

    Amiens, 80054, France

  • CHRU Hopitaux de Brabois

    Vandœuvre-lès-Nancy, 54511, France

  • CHRU Hôpital Haut Lévêque

    Pessac, 33604, France

  • CHU Carémeau

    Nîmes, 30029, France

  • CHU Henri Mondor

    Créteil, 94010, France

  • CHU de Limoges

    Limoges, 87042, France

  • CHU de Nantes

    Nantes, 44093, France

  • Centre Henri Becquerel

    Rouen, 76038, France

  • Centre Hospitalier Annecy Genevois

    Pringy, 74374, France

  • Centre Hospitalier Général

    Dunkirk, 59385, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69495, France

  • Centre Hospitalier Yves Le Foll

    Saint-Brieuc, 22027, France

  • Centre Hospitalier de la côte Basque

    Bayonne, 64109, France

  • Centre Hospitalier départemental de Vendée

    La Roche-sur-Yon, 85925, France

  • Centre René Huguenin

    Saint-Cloud, 92210, France

  • Chru Grenoble

    Grenoble, 38043, France

  • Chu Estaing

    Clermont-Ferrand, 63003, France

  • Clinique Victor Hugo

    Le Mans, 72000, France

  • Hopital Emile Muller

    Mulhouse, 68100, France

  • Hôpital Avicenne

    Bobigny, 93009, France

  • ICH - Hôpital A. Morvan

    Brest, 29609, France

  • Institut Curie

    Paris, 750005, France

  • Institut Paoli Calmette

    Marseille, 13273, France

  • Institut Universitaire du Cancer Toulouse-Oncopôle (IUCT-O)

    Toulouse, 31059, France

  • Institut d'Hématologie de Basse Normandie - IHBN

    Caen, 14033, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.